Results 161 to 170 of about 2,893,970 (365)

Recombinant Human Interleukin-1 Receptor Antagonist in Severe Traumatic Brain Injury: A Phase II Randomized Control Trial

Journal of Cerebral Blood Flow and Metabolism, 2014
A. Helmy, M. Guilfoyle, K. Carpenter, J. Pickard, D. Menon, P. Hutchinson   +5 more
semanticscholar   +1 more source

The subcellular distribution of phosphorylated Y‐box‐binding protein‐1 at S102 in colorectal cancer patients, stratified by KRAS mutational status and clinicopathological features

Molecular Oncology, EarlyView.
This study identifies nuclear YB‐1 S102 phosphorylation as a marker associated with KRAS and FBXW7 mutations in colorectal cancer. Mutated KRAS correlates specifically with nuclear, not cytoplasmic, S102 YB‐1. These findings provide the first ex vivo evidence of this link in CRC and suggest future studies should assess the prognostic and therapeutic ...
Konstanze Lettau, Stephan Forchhammer, Birgit Fehrenbacher, Lejla Mahmutovic, Marcus Scharpf, Gunnar Blumenstock, Martin Schaller, Irina Bonzheim, Shayan Khozooei, Mahmoud Toulany   +9 more
wiley   +1 more source

Efficacy and Safety of Histamine H3 Receptor Antagonist/Inverse Agonist Including Betahistine for Schizophrenia: A Systematic Review and Meta-Analysis. [PDF]

Neuropsychopharmacol Rep
Nishii Y, Sakuma K, Hamanaka S, Iwata N, Kishi T.   +4 more
europepmc   +1 more source

An arylaminopyridazine derivative of gamma-aminobutyric acid (GABA) is a selective and competitive antagonist at the GABAA receptor site. [PDF]

, 1985
J. P. Chambón, P. Feltz, Michel Héaulme, S. Restle, Rémy Schlichter, Kathleen Bizière, Camille G. Wermuth   +6 more
openalex   +1 more source

Therapeutic applications of a novel humanized monoclonal antibody targeting chemokine receptor CCR9 in pancreatic cancer

Molecular Oncology, EarlyView.
C–C chemokine receptor type 9 (CCR9) is an immune checkpoint in pancreatic ductal adenocarcinoma (PDAC). Novel anti‐CCR9 antibody SRB2 was evaluated in combination with cytotoxic chemotherapy in PDAC cells, patient‐derived organoids, patient‐derived xenografts, and humanized mouse models.
Hannah G. McDonald, Anna M. Reagan, Charles J. Bailey, Mei Gao, Muqiang Gao, Angelica L. Solomon, Michael J. Cavnar, Prakash K. Pandalai, Mautin T. Barry‐Hundeyin, Megan M. Harper, Justin A. Rueckert, Ángela Turrero, Araceli Tobio, Anxo Vidal, Daniel Roca‐Lema, Elia Álvarez‐Coiradas, Pablo Garrido, Laureano Simón, Joseph Kim   +18 more
wiley   +1 more source

A Review of the Clinical Progress of CT1812, a Novel Sigma-2 Receptor Antagonist for the Treatment of Alzheimer's Disease. [PDF]

Pharmaceuticals (Basel)
Steinfield SR, Stenn DF, Chen H, Kalisch BE.   +3 more
europepmc   +1 more source

Human fat cell beta-adrenergic receptors: beta-agonist-dependent lipolytic responses and characterization of beta-adrenergic binding sites on human fat cell membranes with highly selective beta 1-antagonists.

, 1988
Pascale Mauriège, Giovanni De Pergola, M Berlan, Max Lafontan   +3 more
openalex   +1 more source

Efficacy of the neurokinin‐1 receptor antagonist aprepitant in children with cyclical vomiting syndrome

Alimentary Pharmacology and Therapeutics, 2014
F. Cristofori, N. Thapar, E. Saliakellis, N. Kumaraguru, M. Elawad, F. Kiparissi, J. Köglmeier, P. Andrews, K. Lindley, O. Borrelli   +9 more
semanticscholar   +1 more source

BMP antagonist CHRDL2 enhances the cancer stem‐cell phenotype and increases chemotherapy resistance in colorectal cancer

Molecular Oncology, EarlyView.
Overexpression of CHRDL2 in colon cancer cells makes them more stem‐like and resistant to chemo‐ and radiotherapy. CHRDL2‐high cells have upregulation of the WNT pathway, genes involved in the DNA damage response (DDR) pathway and epithelial‐to‐mesenchymal transition (EMT). This leads to quicker repair of damaged DNA and more cell migration.
Eloise Clarkson, Annabelle Lewis
wiley   +1 more source

Research trends and performance of endothelin A receptor antagonist in kidney care: a bibliometric analysis. [PDF]

Ren Fail
Cheungpasitporn W, Krisanapan P, Suppadungsuk S, Thongprayoon C, Fülöp T, Miao J, Soliman KM, Ho YS.   +7 more
europepmc   +1 more source